241 related articles for article (PubMed ID: 9646640)
1. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins.
Jonson SD; Welch MJ
Q J Nucl Med; 1998 Mar; 42(1):8-17. PubMed ID: 9646640
[TBL] [Abstract][Full Text] [Related]
2. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
Katzenellenbogen JA; Welch MJ; Dehdashti F
Anticancer Res; 1997; 17(3B):1573-6. PubMed ID: 9179196
[TBL] [Abstract][Full Text] [Related]
3. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
VanBrocklin HF; Carlson KE; Katzenellenbogen JA; Welch MJ
J Med Chem; 1993 May; 36(11):1619-29. PubMed ID: 7684451
[TBL] [Abstract][Full Text] [Related]
4. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
[TBL] [Abstract][Full Text] [Related]
5. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals.
Seimbille Y; Rousseau J; Bénard F; Morin C; Ali H; Avvakumov G; Hammond GL; van Lier JE
Steroids; 2002 Aug; 67(9):765-75. PubMed ID: 12123788
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
8. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas.
Dehdashti F; McGuire AH; Van Brocklin HF; Siegel BA; Andriole DP; Griffeth LK; Pomper MG; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1991 Aug; 32(8):1532-7. PubMed ID: 1869974
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study.
Inoue T; Kim EE; Wallace S; Yang DJ; Wong FC; Bassa P; Cherif A; Delpassand E; Buzdar A; Podoloff DA
Cancer Biother Radiopharm; 1996 Aug; 11(4):235-45. PubMed ID: 10851543
[TBL] [Abstract][Full Text] [Related]
10. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
11. Progesterone receptor targeting with radiolabelled steroids: an approach in predicting breast cancer response to therapy.
Cunha S; Gano L; Morais GR; Thiemann T; Oliveira MC
J Steroid Biochem Mol Biol; 2013 Sep; 137():223-41. PubMed ID: 23669457
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of a positron emitting progestin ([18F]fluoro-16 alpha-methyl-19-norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography.
Verhagen A; Luurtsema G; Pesser JW; de Groot TJ; Wouda S; Oosterhuis JW; Vaalburg W
Cancer Lett; 1991 Aug; 59(2):125-32. PubMed ID: 1884369
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations.
Verhagen A; Studeny M; Luurtsema G; Visser GM; De Goeij CC; Sluyser M; Nieweg OE; Van der Ploeg E; Go KG; Vaalburg W
Nucl Med Biol; 1994 Oct; 21(7):941-52. PubMed ID: 9234348
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer: PET imaging of estrogen receptors.
Mintun MA; Welch MJ; Siegel BA; Mathias CJ; Brodack JW; McGuire AH; Katzenellenbogen JA
Radiology; 1988 Oct; 169(1):45-8. PubMed ID: 3262228
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of 7 alpha-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents.
VanBrocklin HF; Liu A; Welch MJ; O'Neil JP; Katzenellenbogen JA
Steroids; 1994 Jan; 59(1):34-45. PubMed ID: 8140600
[TBL] [Abstract][Full Text] [Related]
16. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
Buckman BO; Bonasera TA; Kirschbaum KS; Welch MJ; Katzenellenbogen JA
J Med Chem; 1995 Jan; 38(2):328-37. PubMed ID: 7830275
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
19. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography.
Verhagen A; Elsinga PH; de Groot TJ; Paans AM; de Goeij CJ; Sluyser M; Vaalburg W
Cancer Res; 1991 Apr; 51(7):1930-3. PubMed ID: 2004378
[TBL] [Abstract][Full Text] [Related]
20. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
